Kenya
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 44 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 9.1 (5.5–12) 20 (12–27)
Mortality (HIV+TB only) 9.5 (7.5–12) 21 (17–27)
Prevalence  (includes HIV+TB) 130 (69–200) 283 (156–447)
Incidence  (includes HIV+TB) 120 (120–120) 268 (261–275)
Incidence (HIV+TB only) 48 (47–50) 109 (105–112)
Case detection, all forms (%) 75 (74–77)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
1 700 (7–3 700) 1 100 (17–2 300)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 34 686   4 632
Pulmonary, clinically diagnosed 32 153   3 847
Extrapulmonary 14 478   0
       
Total new and relapse 89 796    
Previously treated, excluding relapses      
Total cases notified 89 796    
Among 74 335 new cases:
4 383 (6%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 127 (<1%) 1 846 (22%) 2 116
Laboratory-confirmed RR-/MDR-TB cases     160
Patients started on MDR-TB treatment     290
TB/HIV 2013 Number (%)
TB patients with known HIV status 84 178 (94)
HIV-positive TB patients 31 650 (38)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 31 380 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 26 431 (84)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 78
HIV-positive TB cases, all types, registered in 2012 83
RR-/MDR-TB cases started on second-line treatment in 2011 70
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 4.2
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 21
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 57
% Funded domestically 23%
% Funded internationally 17%
% Unfunded 60%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-27 Data: www.who.int/tb/data